Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Characterization of the chimeric retinoic acid receptor RARalpha/VDR

S M Pemrick1, P Abarzúa, C Kratzeisen

  • 1Department of Metabolic Diseases, Hoffmann-La Roche, Inc., Nutley, NJ, USA.

Leukemia
|April 29, 1998
PubMed
Summary

This study engineered a chimeric receptor, RARalpha/VDR, combining retinoic acid and vitamin D receptor domains. RARalpha/VDR effectively targets retinoic acid response elements (RAREs) and influences cell differentiation, offering a novel research tool.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Murine IRF8 Mutation Offers New Insight into Osteoclast and Root Resorption.

Journal of dental research·2024
Same author

Sphingolipid pathway enzymes modulate cell fate and immune responses.

Immunotherapy·2017
Same author

Mysm1 is required for interferon regulatory factor expression in maintaining HSC quiescence and thymocyte development.

Cell death & disease·2016
Same author

Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Specificity of Agrobacterium-mediated delivery of maize streak virus DNA to members of the Gramineae.

Plant molecular biology·2013
Same author

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.

Cancer chemotherapy and pharmacology·2013

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Cell Biology

Background:

  • Chimeric receptors can combine functions of different nuclear receptors.
  • Retinoic acid receptor alpha (RARalpha) and vitamin D receptor (VDR) are key regulators of gene expression.
  • Understanding receptor-ligand interactions is crucial for therapeutic development.

Purpose of the Study:

  • To characterize the novel chimeric receptor RARalpha/VDR.
  • To assess its ligand-binding properties and transcriptional activity.
  • To evaluate its functional effects on cell differentiation.

Main Methods:

  • Construction and expression of chimeric receptors (RARalpha/VDR, RARalpha/ER, ER/RARalpha/ER).
  • Ligand-binding assays and transcriptional activity measurements using reporter genes.

Related Experiment Videos

  • Generation of F9 embryonal carcinoma cell lines expressing RARalpha/VDR.
  • Assessment of cell growth inhibition and differentiation induction.

    • Main Results:

    • RARalpha/VDR exhibits VDR-like ligand-binding (Kd for D3 = 0.5 nM) and RARalpha-like transcriptional activity on RAREs.
    • It forms heterodimers with RXRalpha and binds to the betaRARE.
    • RARalpha/VDR expression in F9 cells confers vitamin D-induced differentiation, unlike wild-type cells.
    • Chimeric receptors with estrogen receptor (ER) domains showed different binding and activity profiles.

    Conclusions:

    • RARalpha/VDR functions as a VDR ligand-binding chimera with RARalpha transcriptional properties.
    • This engineered receptor can specifically target RAREs, augmenting transcription without interfering with endogenous RAR signaling.
    • RARalpha/VDR serves as a valuable tool for studying retinoid pathways and VDR-mediated effects.